A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.